Emmaus Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

STOCKHOLDERS' DEFICIT (Details Narrative)

STOCKHOLDERS' DEFICIT (Details Narrative) - USD ($)			1 Months Ended	3 Months Ended				6 Months Ended	9 Months Ended
STOCKHOLDERS' DEFICIT (Details Narrative) - USD ($)	Feb. 26, 2021	Jun. 15, 2020	Jun. 30, 2022	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Jun. 15, 2022	Dec. 31, 2021	Sep. 29, 2021	Feb. 09, 2021	Dec. 31, 2020
Class Of Warrant Or Right [Line Items]
Convertible notes principal amount				$ 26,143,000					$ 26,143,000			$ 18,007,000
Debt instrument exercise price				$ 2.50					$ 2.50
Warrants granted, term									5 years
Warrants granted to purchase common stock				500,000					500,000
Warrant derivative liabilities				$ 33,000					$ 33,000			$ 1,503,000
Change in fair value of warrant derivative liabilities				$ 51,000		$ (131,000)			$ 1,341,000	$ (322,000)
Weighted average remaining contractual life (years), outstanding									2 years 3 months 18 days
Common stock, issued				49,558,501					49,558,501			49,311,864	4,000,000
Share-based compensation									$ 13,000	548,000
Research and development				$ 432,000		470,000			$ 1,196,000	3,032,000
Adjustment of warrants change in fair value increase additional paid in capital and accumulated loss								$ 446,000
Common stock issued for services					$ 110,000		$ 500,000
Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Common stock issued for services (in shares)					246,637		324,675
Common stock issued for services					$ 1,000
Amended and Restated Warrants [Member]
Class Of Warrant Or Right [Line Items]
Debt instrument exercise price			$ 0.446		$ 0.446			$ 0.446
Number of common stock to be purchased									4,038,200
Kainos Medicine, Inc [Member]
Class Of Warrant Or Right [Line Items]
Payments to research and development expense	$ 500,000
Common stock shares issued for consideration	324,675
Addition to equity for common stock	$ 500,000
Research and development									$ 0	1,000,000.0
Stock Options [Member]
Class Of Warrant Or Right [Line Items]
Vesting period remaining for recognition of unrecognized share-based compensation expense									8 months 12 days
Restricted Stock [Member] \| Professional Relations and Consulting Service [Member] \| Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Common stock issued for services (in shares)			246,637
Common stock issued for services			$ 110,000
2021 Stock Incentive Option Plan [Member]
Class Of Warrant Or Right [Line Items]
Unrecognized share-based compensation expense				8,000					$ 8,000
2021 Stock Incentive Option Plan [Member] \| Stock Options [Member]
Class Of Warrant Or Right [Line Items]
Share-based compensation				$ 3,000		$ 93,000			$ 13,000	$ 548,000
Convertible Promissory Note [Member]
Class Of Warrant Or Right [Line Items]
Number outstanding											1,250,000	1,250,000
Convertible Promissory Note [Member] \| Securities Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Convertible notes principal amount		$ 3,150,000
Extended maturity date		Jun. 15, 2023
Percentage of monthly payments interest rate		12.00%												2.00%	11.00%
Debt instrument exercise price		$ 2.05
Expected life (in years)		5 years
Number outstanding		1,250,000
Outstanding shares repayment		500,000
Repayment of debt		$ 0